Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nyse
  5. Anthem, Inc.
  6. Summary
    ANTM   US0367521038

ANTHEM, INC.

(ANTM)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
10/18/2021 10/19/2021 10/20/2021 10/21/2021 10/22/2021 Date
388.21(c) 393.75(c) 424.05(c) 430.41(c) 433.34(c) Last
928 129 1 319 681 2 376 721 1 606 653 908 844 Volume
-1.23% +1.43% +7.70% +1.50% +0.68% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 138 B - -
Net income 2021 6 119 M - -
Net Debt 2021 16 152 M - -
P/E ratio 2021 17,5x
Yield 2021 0,99%
Sales 2022 152 B - -
Net income 2022 6 504 M - -
Net Debt 2022 15 771 M - -
P/E ratio 2022 16,2x
Yield 2022 1,03%
Capitalization 105 B 105 B -
EV / Sales 2021 0,88x
EV / Sales 2022 0,80x
Nbr of Employees 83 400
Free-Float 99,3%
More Financials
Company
Anthem, Inc. is a health benefits company. The Company operates through four segments: Commercial & Specialty Business, Government Business, IngenioRx and Other. It offers a spectrum of network-based managed care plans to large and small employer, individual, Medicaid and Medicare markets. Its managed care plans include preferred provider organizations; health maintenance organizations; point-of-service plans;... 
Sector
Managed Healthcare
Calendar
01/26Earnings Release
More about the company
Ratings of Anthem, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B+
More Ratings
All news about ANTHEM, INC.
10/22S&P 500 Posts 1.6% Weekly Rise After Hitting New Record High Amid Better-Than-Expected ..
MT
10/22ANTHEM : BMO Capital Adjusts Anthem PT to $500 From $465, Maintains Outperform Rating
MT
10/22ANTHEM : Deutsche Bank Adjusts Anthem PT to $460 From $408, Maintains Buy Rating
MT
10/21ANTHEM : Truist Securities Adjusts Anthem PT to $490 From $450, Maintains Buy Rating
MT
10/21ANTHEM : JPMorgan Adjusts Anthem PT to $467 From $423, Maintains Overweight Rating
MT
10/21ANTHEM : Bernstein Adjusts Anthem PT to $559 From $509, Maintains Outperform Rating
MT
10/21ANTHEM : Stephens Adjusts Price Target on Anthem to $475 from $440, Keeps Overweight Ratin..
MT
10/21ANTHEM : Barclays Adjusts Price Target on Anthem to $485 From $450, Maintains Overweight R..
MT
10/21ANTHEM : Morgan Stanley Adjusts Anthem's Price Target to $486 from $468, Keeps Overweight ..
MT
10/21ANTHEM : SVB Leerink Adjusts Anthem's Price Target to $430 from $403, Keeps Market Perform..
MT
10/21ANTHEM : Credit Suisse Raises Anthem's PT to $486 from $425 After 'Strong' Q3 Results, Kee..
MT
10/21ANTHEM : RBC Boosts Price Target on Anthem to $452 From $408, Maintains Sector Perform Rat..
MT
10/20Dow Jones Industrial Average : Strong earnings reports lift Wall Street
RE
10/20US Stocks Gain for Sixth Day; Dow Sets Intraday Record as Verizon Earnings Impress
MT
10/20CLOSE UPDATE : US Stocks Gain for Sixth Day; Dow Sets Intraday Record as Verizon Earnings ..
MT
More news
News in other languages on ANTHEM, INC.
10/22L'indice S&P 500 affiche une hausse hebdomadaire de 1,6 % après avoir atteint un nouvea..
10/20DOW JONES INDUSTRIAL AVERAGE : Wall Street cierra en alza, resultados de empresas alivian ..
10/20Les actions américaines progressent pour la sixième journée ; le Dow Jones établit un r..
10/20CLOSE UPDATE : Les actions américaines progressent pour la sixième journée ; le Dow Jones ..
10/20Les actions du secteur de la santé en hausse pour la deuxième journée consécutive
More news
Analyst Recommendations on ANTHEM, INC.
More recommendations
Chart ANTHEM, INC.
Duration : Period :
Anthem, Inc. Technical Analysis Chart | ANTM | US0367521038 | MarketScreener
Technical analysis trends ANTHEM, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 25
Last Close Price 433,34 $
Average target price 461,17 $
Spread / Average Target 6,42%
EPS Revisions
Managers and Directors
Gail Koziara Boudreaux President, Chief Executive Officer & Director
John Edward Gallina Chief Financial Officer & Executive Vice President
Elizabeth E. Tallett Independent Chairman
Gloria M. McCarthy Chief Administrative Officer & Executive VP
Ramiro G. Peru Independent Director
Sector and Competitors
1st jan.Capi. (M$)
ANTHEM, INC.34.05%105 178
UNITEDHEALTH GROUP24.07%417 033
CIGNA CORPORATION3.16%73 541
HUMANA INC.10.78%59 216
CENTENE CORPORATION14.93%40 224
MOLINA HEALTHCARE, INC.39.29%17 301